Tearsheet

Precigen (PGEN)

Market Price (6/15/2026): $4.47 | Market Cap: $1.6 BilSector: Health Care | Industry: Biotechnology

Precigen (PGEN)

Market Price (6/15/2026): $4.47
Market Cap: $1.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 652%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -67%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more.

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -90 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -285%

Stock price has recently run up significantly
12M Rtn12 month market price return is 193%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 35%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -365%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -370%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17%

High stock price volatility
Vol 12M is 105%

Key risks
PGEN key risks include [1] a history of substantial net losses and a high cash burn rate necessitating additional financing, Show more.

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 652%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -67%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more.
3	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -90 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -285%
5	Stock price has recently run up significantly 12M Rtn12 month market price return is 193%
6	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 35%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -365%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -370%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17%
9	High stock price volatility Vol 12M is 105%
10	Key risks PGEN key risks include [1] a history of substantial net losses and a high cash burn rate necessitating additional financing, Show more.

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	6/15/26	2025	2024	2023	2022
Share Price			$4.47	$4.18	$1.12	$1.34	$1.52
Mkt Cap ($ Bil)			1.6	1.5	0.3	0.3	0.3
+ Debt ($ Bil)			0.1	0.1	0.0	0.0	0.1
- Cash ($ Bil)			0.1	0.1	0.1	0.1	0.1
TEV ($ Bil)			1.6	1.6	0.3	0.3	0.4
Valuation Ratios
P/S	6.9	12.7	50.1	152.9	83.6	53.6	11.3
P/EBIT	—	—	-8.0	-6.0	-2.6	-3.5	-4.2
P/E	21.1	—	-7.7	-5.9	-2.6	-3.5	10.8
P/FCF	—	—	-13.5	-16.5	-4.3	-4.9	-4.4
Sector Ratios (* = sector average)
P/S *			3.7	4.2	3.8	4.2	4.6
P/EBIT *			-1.7	-1.7	-1.5	-1.5	-1.3
P/E *			-1.8	-1.8	-1.7	-1.7	-1.3
P/FCF *			-1.9	-1.8	-1.5	-1.6	-1.6

FYE: 12/31	Forward FYE		Now
	2027	2026	6/15/26
Share Price			$4.47
Mkt Cap ($ Bil)			1.6
+ Debt ($ Bil)			0.1
- Cash ($ Bil)			0.1
TEV ($ Bil)			1.6
Valuation Ratios
P/S	6.9	12.7	50.1
P/EBIT	—	—	-8.0
P/E	21.1	—	-7.7
P/FCF	—	—	-13.5
Sector Ratios (* = sector average)
P/S *			3.7
P/EBIT *			-1.7
P/E *			-1.8
P/FCF *			-1.9

FYE: 12/31	PGEN [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$31.6 Mil	—
FY 2026 Sales	$124.4 Mil	—
FY 2027 Sales	$229.0 Mil	—
FY 2026 Sales Growth	293.8%	—
FY 2027 Sales Growth	84.1%	7.8%
EARNINGS
LTM Net Income (GAAP) [3]	$-204.4 Mil	—
FY 2026 Net Income (Non-GAAP)	$-8.9 Mil	—
FY 2027 Net Income (Non-GAAP)	$75.1 Mil	—
FY 2027 Net Income Growth	—	14.6%
FY 2026 EPS (Non-GAAP)	$-0.03	—
FY 2027 EPS (Non-GAAP)	$0.20	—
FY 2027 EPS Growth	—	—
VALUATION
FY 2026 P/S	12.7	3.3
FY 2027 P/S	6.9	—
FY 2026 P/E	—	20.4
FY 2027 P/E	21.1	—

[1] PGEN forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 6/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

	PGEN	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.0
Rev Chg Q	1,633.9%	8.8%
Rev Chg LTM	652.1%	7.4%
Rev Chg 3Y Avg	184.2%	5.8%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.2
Op Mgn LTM	-284.8%	18.4%
CFO/Rev LTM	-365.0%	21.3%
Net Inc Mgn	-647.0%	13.0%
VALUATION	VERY HIGH
P/S	50.1	3.3
P/CFO	-13.7	15.2
P/FCF	-13.5	19.7
P/E	-7.7	24.2
STABILITY	VERY GOOD
Debt/Equity	0.06	0.21
Cash/Assets	0.41	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
PRGN-2012 Phase 1/2 Pivotal Study Patients	35	6032024	Link
PRGN-2012 Complete Response Rate	51%	6032024	Link
Reduction in Surgeries for PRGN-2012 Treated Patients	86%	6032024	Link
PDUFA Target Action Date for PRGN-2012	2025-08-27	2252025	Link
Estimated Adult RRP Patients in the US	approximately 27,000	5142025	Link
Estimated RRP Patients outside of the US	more than 125,000	5142025	Link
PRGN-3006 Phase 1b AML Trial Enrollment Status	Completed	8062024	Link

Price Chart

Upcoming
8/11/2026	Earnings Release	Rev: $27 Mil (E) EPS: $-0.02 (E)

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/11/2026

Precigen (PGEN) stock has gained about 15% since 2/28/2026 because of the following key factors:

1. Strong Q1 2026 Earnings Beat Driven by PAPZIMEOS Commercial Launch.

Precigen reported better-than-expected financial results for its fiscal Q1 2026, which ended on March 31, 2026. The company posted an EPS of -$0.02, surpassing analyst forecasts of -$0.03 by 33%. Total revenue reached $23.25 million, exceeding the estimated $20.8 million by 11.4% and marking a significant increase from Q4 2025's $3.4 million. This strong revenue growth was primarily fueled by PAPZIMEOS, an immunotherapy for recurrent respiratory papillomatosis (RRP), which generated $21.6 million in net product revenue during its first full commercial quarter. The robust performance led to a substantial narrowing of the net loss by approximately 85% year-over-year to $7.9 million and a stock surge of about 10.84% in aftermarket trading following the May 13, 2026, earnings report.

2. Key Regulatory Milestones and Market Exclusivity for PAPZIMEOS.

Precigen achieved significant regulatory milestones for PAPZIMEOS, bolstering its commercial prospects. On May 27, 2026, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Exclusivity for PAPZIMEOS, providing seven years of market exclusivity. Additionally, a permanent J-code for PAPZIMEOS became effective on April 1, 2026, which is expected to streamline claims processing and broaden patient access across healthcare settings. Further solidifying its market position, an expert position paper in January 2026 recommended PAPZIMEOS as the new standard of care first-line treatment for adults with RRP in the United States.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 17.4% change in PGEN stock from 2/28/2026 to 6/14/2026 was primarily driven by a 400.8% change in the company's Total Revenues ($ Mil).

(LTM values as of)	2282026	6142026	Change
Stock Price ($)	3.79	4.45	17.4%
Change Contribution By:
Total Revenues ($ Mil)	6	32	400.8%
P/S Multiple	184.5	49.9	-73.0%
Shares Outstanding (Mil)	307	354	-13.3%
Cumulative Contribution			17.4%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/14/2026

	Return	Correlation
PGEN	17.4%
Market (SPY)	8.4%	30.3%
Sector (XLV)	-3.6%	25.4%

Fundamental Drivers

The 16.2% change in PGEN stock from 11/30/2025 to 6/14/2026 was primarily driven by a 400.8% change in the company's Total Revenues ($ Mil).

(LTM values as of)	11302025	6142026	Change
Stock Price ($)	3.83	4.45	16.2%
Change Contribution By:
Total Revenues ($ Mil)	6	32	400.8%
P/S Multiple	186.5	49.9	-73.2%
Shares Outstanding (Mil)	307	354	-13.3%
Cumulative Contribution			16.2%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/14/2026

	Return	Correlation
PGEN	16.2%
Market (SPY)	9.2%	25.4%
Sector (XLV)	-1.6%	25.6%

Fundamental Drivers

The 237.1% change in PGEN stock from 5/31/2025 to 6/14/2026 was primarily driven by a 652.1% change in the company's Total Revenues ($ Mil).

(LTM values as of)	5312025	6142026	Change
Stock Price ($)	1.32	4.45	237.1%
Change Contribution By:
Total Revenues ($ Mil)	4	32	652.1%
P/S Multiple	92.3	49.9	-46.0%
Shares Outstanding (Mil)	294	354	-17.1%
Cumulative Contribution			237.1%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/14/2026

	Return	Correlation
PGEN	237.1%
Market (SPY)	27.3%	18.5%
Sector (XLV)	18.0%	21.3%

Fundamental Drivers

The 273.9% change in PGEN stock from 5/31/2023 to 6/14/2026 was primarily driven by a 324.3% change in the company's P/S Multiple.

(LTM values as of)	5312023	6142026	Change
Stock Price ($)	1.19	4.45	273.9%
Change Contribution By:
Total Revenues ($ Mil)	23	32	35.9%
P/S Multiple	11.8	49.9	324.3%
Shares Outstanding (Mil)	230	354	-35.1%
Cumulative Contribution			273.9%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2023 to 6/14/2026

	Return	Correlation
PGEN	273.9%
Market (SPY)	84.5%	29.8%
Sector (XLV)	26.5%	27.9%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
PGEN Return	-64%	-59%	-12%	-16%	273%	8%	-56%
Peers Return	-26%	-62%	19%	-52%	-3%	29%	-80%
S&P 500 Return	27%	-19%	24%	23%	16%	8%	97%
Monthly Win Rates [3]
PGEN Win Rate	17%	33%	42%	50%	67%	83%
Peers Win Rate	33%	33%	45%	33%	43%	57%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
PGEN Max Drawdown	-68%	-71%	-60%	-64%	-42%	-40%
Peers Max Drawdown	-66%	-68%	-56%	-71%	-61%	-32%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, NTLA, EDIT, IOVA, NKTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/12/2026 (YTD)

Event	PGEN	S&P 500
2025 US Tariff Shock
% Loss	-42.4%	-18.8%
% Gain to Breakeven	73.5%	23.1%
Time to Breakeven	129 days	79 days
2024 Yen Carry Trade Unwind
% Loss	-30.5%	-7.8%
% Gain to Breakeven	43.9%	8.5%
Time to Breakeven	178 days	18 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-28.8%	-9.5%
% Gain to Breakeven	40.4%	10.5%
Time to Breakeven	31 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-44.7%	-6.7%
% Gain to Breakeven	81.0%	7.1%
Time to Breakeven	140 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-71.1%	-24.5%
% Gain to Breakeven	246.1%	32.4%
Time to Breakeven	1201 days	427 days
2020 COVID-19 Crash
% Loss	-68.2%	-33.7%
% Gain to Breakeven	214.4%	50.9%
Time to Breakeven	94 days	140 days

Compare to CRSP, NTLA, EDIT, IOVA, NKTX

In The Past

Precigen's stock fell -42.4% during the 2025 US Tariff Shock. Such a loss loss requires a 73.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	PGEN	S&P 500
2025 US Tariff Shock
% Loss	-42.4%	-18.8%
% Gain to Breakeven	73.5%	23.1%
Time to Breakeven	129 days	79 days
2024 Yen Carry Trade Unwind
% Loss	-30.5%	-7.8%
% Gain to Breakeven	43.9%	8.5%
Time to Breakeven	178 days	18 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-28.8%	-9.5%
% Gain to Breakeven	40.4%	10.5%
Time to Breakeven	31 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-44.7%	-6.7%
% Gain to Breakeven	81.0%	7.1%
Time to Breakeven	140 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-71.1%	-24.5%
% Gain to Breakeven	246.1%	32.4%
Time to Breakeven	1201 days	427 days
2020 COVID-19 Crash
% Loss	-68.2%	-33.7%
% Gain to Breakeven	214.4%	50.9%
Time to Breakeven	94 days	140 days
2013 Taper Tantrum
% Loss	-28.6%	-0.2%
% Gain to Breakeven	40.1%	0.2%
Time to Breakeven	62 days	1 days

Compare to CRSP, NTLA, EDIT, IOVA, NKTX

In The Past

Precigen's stock fell -42.4% during the 2025 US Tariff Shock. Such a loss loss requires a 73.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Precigen (PGEN)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

AI Analysis | Feedback

Like CRISPR Therapeutics, but with a broader set of advanced genetic and cellular engineering platforms for diverse next-generation therapies.
Imagine Moderna developing cutting-edge therapies, but Precigen focuses on building and utilizing a diverse suite of genetic and cellular engineering platforms to create a wider range of next-generation treatments.

AI Analysis | Feedback

Precigen (PGEN) Major Products and Platforms

Gene and Cellular Therapies: Precigen discovers and develops advanced treatments by engineering genes and cells.
Disease-Modifying Therapeutics: These therapies are designed to alter the progression of various diseases.
Genetically Engineered Swine: The company provides swine specifically modified for regenerative medicine applications.
UltraVector Platform: This technology platform designs and assembles complex gene expression programs using advanced DNA construction.
UltraCAR-T Platform: A specialized platform for developing CAR-T cell therapies to treat cancer.
AdenoVerse Platform: This platform utilizes a library of engineered adenovectors for gene delivery and immunotherapy.
ActoBiotics Platform: A platform employing genetically modified bacteria to deliver therapeutic proteins and peptides at mucosal sites.
Sleeping Beauty System: A non-viral transposon/transposase system used for efficient gene delivery and engineering.
RheoSwitch System: An inducible gene switch system enabling precise, dose-proportionate control over gene expression.
Kill Switches: Engineered genetic mechanisms designed to selectively eliminate cell therapies in vivo for enhanced safety.

AI Analysis | Feedback

Precigen (PGEN) primarily sells its technologies, platforms, and services to other companies in the biotechnology, pharmaceutical, and research sectors through collaboration and license agreements.

Based on the provided description, its major customers and partners include:

Alaunos Therapeutics, Inc. (Symbol: TCRT)
Ares Trading S.A. (Not publicly traded as a standalone entity)
Oragenics, Inc. (Symbol: OGEN)
Castle Creek Biosciences, Inc. (Private company)
Intrexon Energy Partners, LLC (Private company)
Intrexon Energy Partners II, LLC (Private company)

AI Analysis | Feedback

null

AI Analysis | Feedback

Helen Sabzevari, PhD – President, Chief Executive Officer, and Director

Dr. Helen Sabzevari was appointed CEO of Precigen in January 2020. She has dedicated her career to eradicating disease, contributing to the development of multiple therapeutics for various cancers, autoimmune disorders, and infectious diseases. Dr. Sabzevari cofounded Compass Therapeutics in 2015, serving as its Chief Scientific Officer until 2017. Prior to Precigen, she held executive leadership positions at Merck KGaA, where she helped bring forth Bavencio, an anti-PD-L1 checkpoint inhibitor, and the National Institutes of Health (NIH), where she led the Molecular Immunology Group at the Laboratory of Tumor Immunology and Biology. She holds a doctorate in cell and molecular immunology and received the National Institutes of Health (NIH) merit award for her work in immuno-oncology.

Harry Thomasian, Jr. – Chief Financial Officer and Principal Accounting Officer

Mr. Harry Thomasian, Jr. is a global finance leader with over 35 years of international business experience. His expertise encompasses equity and debt financings, P&L management, business operations, regulatory compliance, generally accepted accounting principles, SEC filings, and Sarbanes-Oxley compliance. Before joining Precigen, Mr. Thomasian was with EY (formerly Ernst & Young LLP), a global professional services firm, where he served as a Senior Client Services Partner, the Baltimore Office Growth Markets Leader for the life sciences industry, and a Senior Partner in EY's Capital Markets Center in Tokyo. He is a licensed certified public accountant in multiple states and jurisdictions.

Rutul R. Shah – Chief Operating Officer

Mr. Rutul R. Shah was named Chief Operating Officer in September 2021.

Donald P. Lehr – Chief Legal Officer

Mr. Donald P. Lehr possesses extensive experience in corporate, securities, and general business law. Before his tenure at Intrexon (now Precigen), he worked at Hogan Lovells LLP, where his practice involved representing privately and publicly held corporations across diverse sectors, including biotechnology, pharmaceuticals, healthcare, software, technology, and manufacturing. He also served as a judicial clerk for the Honorable Irma S. Raker of the Court of Appeals of Maryland.

Phil Tennant – Chief Commercial Officer

Mr. Phil Tennant's current focus is on the commercial launch of Papzimeos, which received approval in August 2025.

AI Analysis | Feedback

The key risks to Precigen's business, which trades under the symbol PGEN, revolve around its financial stability, the commercial success of its recently approved gene therapy, and the progress of its broader development pipeline.

Financial Stability and Cash Burn: Precigen has consistently incurred significant net losses and has been "quickly burning through cash." While the company secured up to $125 million in non-dilutive financing in September 2025, and management aims for cash flow breakeven by late 2026 or early 2027, the substantial operating expenses associated with commercializing its first product raise concerns about its ability to maintain a sufficient cash runway. The company has a notably high debt-to-equity ratio.
Single Asset Dependency and Commercialization Risk of PAPZIMEOS: Precigen's investment narrative is heavily reliant on the successful commercial launch and market uptake of PAPZIMEOS (formerly PRGN-2012), its first and currently only FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP). Risks include potential payer pushback on pricing and reimbursement, slower-than-expected patient uptake, and competition from existing off-label drugs and investigational assets, such as INO-3107. A failure to meet revenue expectations for PAPZIMEOS could severely impact the company's financial outlook and its ability to achieve cash flow breakeven.
Clinical Trial Setbacks and Pipeline Risk: Although PAPZIMEOS has achieved approval, the long-term value and growth of Precigen are tied to the continued advancement and success of its broader gene and cell therapy pipeline, including its UltraCAR-T and AdenoVerse programs. The company has recently prioritized the development of PAPZIMEOS, leading to the pausing of other UltraCAR-T clinical programs and all preclinical programs, as well as the shutdown of its ActoBio subsidiary. Any delays or negative data from ongoing or future clinical trials for these remaining pipeline assets could significantly impact the company's stock value and future prospects.

AI Analysis | Feedback

null

AI Analysis | Feedback

Precigen (PGEN) operates in several significant addressable markets with its gene and cellular therapies.

UltraCAR-T Platform (for cancer treatment)

The global CAR T-cell therapy market, which includes Precigen's UltraCAR-T platform for cancer treatment, was estimated to be between approximately USD 4.20 billion and USD 20.54 billion in 2025. This market is projected to grow significantly, potentially reaching between USD 9.95 billion by 2030 and USD 268.0 billion by 2035.

AdenoVerse Immunotherapy (e.g., PAPZIMEOS for Recurrent Respiratory Papillomatosis - RRP)

For its AdenoVerse Immunotherapy platform, particularly for PAPZIMEOS in Recurrent Respiratory Papillomatosis (RRP), the estimated addressable patient population in the U.S. is approximately 27,000 adults. More broadly, the global oncolytic virus therapy market, of which AdenoVerse immunotherapy is a part, has varying estimates. One report valued the global oncolytic virus therapy market size at USD 411.4 million in 2024, projected to grow to USD 3.22 billion by 2033. Another source estimated the global oncolytic adenovirus market to be valued at USD 140.2 billion in 2025, projected to reach USD 288.9 billion by 2035.

ActoBiotics Platform (genetically modified bacteria for mucosal sites, e.g., Type 1 Diabetes)

Precigen's ActoBiotics platform, which delivers proteins and peptides at mucosal sites, falls within the oral transmucosal drugs and transmucosal drug delivery devices markets. The global oral transmucosal drugs market was valued at approximately USD 36.72 billion in 2024 and is expected to reach around USD 70.37 billion by 2034. Another estimate places the global oral transmucosal drugs market size at USD 45.82 billion in 2025, projected to reach USD 96.8 billion by 2033. The global transmucosal drug delivery devices market was valued at approximately USD 46.63 billion in 2024 and is predicted to grow to around USD 86.64 billion by 2034.

Genetically Engineered Swine (for regenerative medicine/xenotransplantation)

The market for genetically engineered swine for regenerative medicine applications, including xenotransplantation, is also substantial. The global xenotransplantation market was valued at approximately USD 14.68 billion in 2024, growing to USD 15.82 billion in 2025. Other estimates place the global market value at USD 47.9 billion in 2024, projected to reach USD 109.7 billion by 2034, or from USD 3.12 billion in 2025 to around USD 7.26 billion by 2034. The U.S. xenotransplantation market was valued at USD 13.8 billion in 2024 and is forecasted to reach USD 32.7 billion by 2034.

AI Analysis | Feedback

Precigen (PGEN) is expected to experience significant revenue growth over the next two to three years, primarily driven by the following factors:

Commercialization and Market Penetration of PAPZIMEOS for Adult Recurrent Respiratory Papillomatosis (RRP): The commercial launch and rapid adoption of PAPZIMEOS (zopapogene imadenovec) for adult RRP, following its full FDA approval in August 2025, is a primary driver of near-term revenue. Increased patient uptake, broad insurer coverage (including Medicare and Medicaid), and its endorsement as a first-line therapy are expected to contribute to accelerated sales.
Geographic Expansion and New Indications for PAPZIMEOS: Beyond the current adult RRP market in the US, future revenue growth is anticipated from the ongoing geographic expansion of PAPZIMEOS, including submissions to regulatory bodies like the European Medicines Agency (EMA), and the initiation of pediatric clinical trials to address younger patient populations with RRP.
Advancement of the Gene and Cell Therapy Pipeline: Precigen's robust pipeline of differentiated gene and cell therapies across immuno-oncology, autoimmune disorders, and infectious diseases, leveraging proprietary platforms such as UltraCAR-T and AdenoVerse, is expected to provide long-term revenue optionality as these programs progress through clinical development towards potential commercialization.

AI Analysis | Feedback

Share Issuance

Precigen experienced a substantial increase in its outstanding shares, growing from approximately 206.74 million at the end of 2021 to 307.17 million by February 2026.
In 2024, the net issuance of preferred shares amounted to $79.0 million.
The conversion of Series A Convertible Perpetual Preferred Stock into common stock has also contributed to share issuance.

Inbound Investments

In September 2025, Precigen secured a non-dilutive credit facility of up to $125 million with investment funds managed by Pharmakon Advisors, LP.
The initial tranche of $100 million from this credit facility was funded at closing.
An additional $25 million from the credit facility can be drawn at Precigen's discretion through March 31, 2027.

Capital Expenditures

Capital expenditures for Precigen were approximately $0.389 million in Q3 2025.
Over the last 12 months, Precigen's capital expenditures totaled approximately $3.01 million.
These capital investments are focused on long-term sustainable strategies, likely including innovative research and development efforts.

Interactive Breakdown

null

null

Better Bets vs. Precigen (PGEN)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for PGEN: 184.2% | 49.9x)

ARWR (454.7% | 17.1x)

Arrowhead Pharmaceuticals

TGTX (1130.2% | 10.2x)

TG Therapeutics

ARQT (580.2% | 7.6x)

Arcutis Biotherapeutics

TARS (210.4% | 5.0x)

Tarsus Pharmaceuticals

IDYA (998.7% | 11.4x)

IDEAYA Biosciences

Higher Rev Chg LTM (Value for PGEN: 652.1%)

VRDN (23382.8%)

Viridian Therapeutics

IDYA (3118.1%)

IDEAYA Biosciences

CRNX (2277.5%)

Crinetics Pharmaceuticals

NUVB (1205.5%)

Nuvation Bio

CGON (666.0%)

CG Oncology

Higher Rev Chg 3Y Avg (Value for PGEN: 184.2%)

PTGX (12155.6%)

Protagonist Therapeutics

IBRX (3513.8%)

ImmunityBio

TGTX (1130.2%)

TG Therapeutics

ARWR (454.7%)

Arrowhead Pharmaceuticals

CYTK (255.5%)

Cytokinetics

Higher Op Mgn LTM (Value for PGEN: -284.8%)

GILD (40.0%)

Gilead Sciences

VRTX (38.2%)

Vertex Pharmaceuticals

ABBV (33.2%)

AbbVie

AMGN (28.4%)

Amgen

REGN (25.8%)

Regeneron Pharmaceuticals

Higher CFO/Rev LTM (Value for PGEN: -365.0%)

GILD (36.3%)

Gilead Sciences

VRTX (34.7%)

Vertex Pharmaceuticals

ABBV (33.8%)

AbbVie

REGN (33.6%)

Regeneron Pharmaceuticals

AMGN (28.9%)

Amgen

Higher FCF/Rev LTM (Value for PGEN: -370.2%)

GILD (34.4%)

Gilead Sciences

ABBV (31.8%)

AbbVie

VRTX (30.4%)

Vertex Pharmaceuticals

REGN (25.4%)

Regeneron Pharmaceuticals

AMGN (23.1%)

Amgen

Higher Total Yield (Value for PGEN: -13.0%)

GILD (8.5%)

Gilead Sciences

REGN (7.5%)

Regeneron Pharmaceuticals

AMGN (6.8%)

Amgen

VRTX (3.8%)

Vertex Pharmaceuticals

ABBV (3.8%)

AbbVie

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for PGEN: 184.2% | 49.9x)

ARWR (454.7% | 17.1x)

Arrowhead Pharmaceuticals

TGTX (1130.2% | 10.2x)

TG Therapeutics

LQDA (639.8% | 21.8x)

Liquidia

ARQT (580.2% | 7.6x)

Arcutis Biotherapeutics

TARS (210.4% | 5.0x)

Tarsus Pharmaceuticals

Higher Rev Chg LTM (Value for PGEN: 652.1%)

IDYA (3118.1%)

IDEAYA Biosciences

CRNX (2277.5%)

Crinetics Pharmaceuticals

LQDA (1936.7%)

Liquidia

NUVB (1205.5%)

Nuvation Bio

CGON (666.0%)

CG Oncology

Higher Rev Chg 3Y Avg (Value for PGEN: 184.2%)

PTGX (12155.6%)

Protagonist Therapeutics

IBRX (3513.8%)

ImmunityBio

TGTX (1130.2%)

TG Therapeutics

ARWR (454.7%)

Arrowhead Pharmaceuticals

CYTK (255.5%)

Cytokinetics

Higher Op Mgn LTM (Value for PGEN: -284.8%)

LLY (47.3%)

Eli Lilly

ABBV (33.2%)

AbbVie

JNJ (26.8%)

Johnson & Johnson

MRK (19.7%)

Merck

UNH (4.2%)

UnitedHealth

Higher CFO/Rev LTM (Value for PGEN: -365.0%)

ABBV (33.8%)

AbbVie

LLY (28.3%)

Eli Lilly

MRK (27.2%)

Merck

JNJ (23.7%)

Johnson & Johnson

UNH (5.1%)

UnitedHealth

Higher FCF/Rev LTM (Value for PGEN: -370.2%)

ABBV (31.8%)

AbbVie

MRK (21.5%)

Merck

JNJ (18.1%)

Johnson & Johnson

LLY (14.4%)

Eli Lilly

UNH (4.4%)

UnitedHealth

Higher Total Yield (Value for PGEN: -13.0%)

MRK (5.8%)

Merck

JNJ (5.8%)

Johnson & Johnson

UNH (5.4%)

UnitedHealth

ABBV (3.8%)

AbbVie

LLY (3.0%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for PGEN: 184.2% | 49.9x)

CRCL (345.4% | 6.6x)

Circle Internet

NLY (290.4% | 6.7x)

Annaly Capital Management

QXO (5076.7% | 1.4x)

QXO

LBRDA (8202.0% | 18.7x)

Liberty Broadband

ONDS (330.1% | 43.0x)

Ondas

Higher Rev Chg LTM (Value for PGEN: 652.1%)

JOBY (69873.9%)

Joby Aviation

QXO (15211.3%)

QXO

ASTS (1732.1%)

AST SpaceMobile

ONDS (793.2%)

Ondas

MRP (761.8%)

Millrose Properties

Higher Rev Chg 3Y Avg (Value for PGEN: 184.2%)

QXO (5076.7%)

QXO

ASTS (821.2%)

AST SpaceMobile

CRCL (345.4%)

Circle Internet

NLY (290.4%)

Annaly Capital Management

BMNR (284.1%)

BitMine Immersion Technologies

Higher Op Mgn LTM (Value for PGEN: -284.8%)

NVDA (64.0%)

NVIDIA

MSFT (46.8%)

Microsoft

GOOGL (32.7%)

Alphabet

AAPL (32.6%)

Apple

AMZN (11.5%)

Amazon.com

Higher CFO/Rev LTM (Value for PGEN: -365.0%)

MSFT (53.5%)

Microsoft

NVDA (49.6%)

NVIDIA

GOOGL (41.3%)

Alphabet

AAPL (31.1%)

Apple

AMZN (20.0%)

Amazon.com

Higher FCF/Rev LTM (Value for PGEN: -370.2%)

NVDA (47.0%)

NVIDIA

AAPL (28.6%)

Apple

MSFT (22.9%)

Microsoft

GOOGL (15.2%)

Alphabet

AMZN (-0.3%)

Amazon.com

Higher Total Yield (Value for PGEN: -13.0%)

MSFT (5.2%)

Microsoft

GOOGL (3.9%)

Alphabet

AMZN (3.5%)

Amazon.com

AAPL (3.2%)

Apple

NVDA (3.2%)

NVIDIA

Best Bets in Health Care

What You Pay

P/EBIT (Value for PGEN: -8.0x)

RPRX (14.1x)

Royalty Pharma

VEEV (27.3x)

Veeva Systems

DOCS (17.2x)

Doximity

HALO (15.7x)

Halozyme Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

GILD (13.3x)

Gilead Sciences

RMD (14.8x)

ResMed

EXEL (14.3x)

Exelixis

BMY (10.2x)

Bristol-Myers Squibb

NBIX (20.1x)

Neurocrine Biosciences

P/E (Value for PGEN: -7.7x)

RPRX (29.0x)

Royalty Pharma

VEEV (27.7x)

Veeva Systems

DOCS (18.9x)

Doximity

HALO (23.5x)

Halozyme Therapeutics

CPRX (17.3x)

Catalyst Pharmaceuticals

GILD (16.9x)

Gilead Sciences

RMD (18.6x)

ResMed

EXEL (16.5x)

Exelixis

BMY (16.0x)

Bristol-Myers Squibb

NBIX (24.0x)

Neurocrine Biosciences

What You Get

Rev Chg 3Y Avg (Value for PGEN: 184.2%)

RPRX (1.3%)

Royalty Pharma

VEEV (15.1%)

Veeva Systems

DOCS (15.5%)

Doximity

HALO (29.1%)

Halozyme Therapeutics

CPRX (34.0%)

Catalyst Pharmaceuticals

GILD (3.2%)

Gilead Sciences

RMD (11.3%)

ResMed

EXEL (12.9%)

Exelixis

BMY (1.9%)

Bristol-Myers Squibb

NBIX (24.8%)

Neurocrine Biosciences

Rev Chg LTM (Value for PGEN: 652.1%)

RPRX (7.8%)

Royalty Pharma

VEEV (16.2%)

Veeva Systems

DOCS (13.1%)

Doximity

HALO (39.1%)

Halozyme Therapeutics

CPRX (11.7%)

Catalyst Pharmaceuticals

GILD (3.5%)

Gilead Sciences

RMD (10.3%)

ResMed

EXEL (3.3%)

Exelixis

BMY (1.8%)

Bristol-Myers Squibb

NBIX (28.6%)

Neurocrine Biosciences

Rev Chg Q (Value for PGEN: 1633.9%)

RPRX (11.0%)

Royalty Pharma

VEEV (16.3%)

Veeva Systems

DOCS (5.1%)

Doximity

HALO (42.2%)

Halozyme Therapeutics

CPRX (5.6%)

Catalyst Pharmaceuticals

GILD (4.4%)

Gilead Sciences

RMD (10.8%)

ResMed

EXEL (10.0%)

Exelixis

BMY (2.6%)

Bristol-Myers Squibb

NBIX (42.2%)

Neurocrine Biosciences

FCF/Rev 3Y Avg (Value for PGEN: -1139.6%)

RPRX (114.4%)

Royalty Pharma

VEEV (46.4%)

Veeva Systems

DOCS (44.5%)

Doximity

HALO (39.9%)

Halozyme Therapeutics

CPRX (34.9%)

Catalyst Pharmaceuticals

GILD (32.5%)

Gilead Sciences

RMD (28.6%)

ResMed

EXEL (27.2%)

Exelixis

BMY (26.5%)

Bristol-Myers Squibb

NBIX (26.0%)

Neurocrine Biosciences

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Precigen Earnings Notes	12/16/2025
2	With Precigen Stock Surging, Have You Considered The Downside?	10/17/2025
3	Precigen Stock Up 17% in One Week, Why You Shouldn Not Be Buying The Stock	08/09/2025
4	Precigen (PGEN) EBITDA Comparison	08/08/2025
5	Precigen (PGEN) Net Income Comparison	08/08/2025
6	Precigen (PGEN) Debt Comparison	08/08/2025
7	Precigen (PGEN) Operating Cash Flow Comparison	08/08/2025
8	Precigen (PGEN) Revenue Comparison	08/08/2025
9	Precigen (PGEN) Tax Expense Comparison	08/08/2025
10	Precigen (PGEN) Operating Income Comparison	08/08/2025
11	ARTICLES
12	Market Movers \| Winners: PGEN, RUN, UP \| Losers: NUTX, GTN-A, AMAT	08/16/2025

	Title
0	DASHBOARDS
1	Precigen Earnings Notes
2	With Precigen Stock Surging, Have You Considered The Downside?
3	Precigen Stock Up 17% in One Week, Why You Shouldn Not Be Buying The Stock
4	Precigen (PGEN) EBITDA Comparison
5	Precigen (PGEN) Net Income Comparison
6	Precigen (PGEN) Debt Comparison
7	Precigen (PGEN) Operating Cash Flow Comparison
8	Precigen (PGEN) Revenue Comparison
9	Precigen (PGEN) Tax Expense Comparison
10	Precigen (PGEN) Operating Income Comparison
11	ARTICLES
12	Market Movers \| Winners: PGEN, RUN, UP \| Losers: NUTX, GTN-A, AMAT

Trade Ideas

Select ideas related to PGEN.

null

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ROKU	Roku	21.2	20.1%	32.4%
TBN	Tamboran Resources	0.9	19.9%	48.3%
STTK	Shattuck Labs	0.6	18.2%	35.3%
SENEA	Seneca Foods	1.2	17.5%	58.5%
ALMS	Alumis	3.0	15.6%	147.4%
ELVN	Enliven Therapeutics	2.9	14.3%	199.5%
AKTS	Aktis Oncology	1.1	12.7%	∞%
ZBIO	Zenas BioPharma	1.1	11.5%	-45.5%
POET	POET Technologies	1.8	11.4%	97.9%
VYX	NCR Voyix	1.1	10.3%	-23.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	5.1	-19.1%	42.5%
YSS	York Space Systems	3.5	-17.9%	-17.6%
VELO	Velo3D	0.5	-16.7%	85.6%
ASTS	AST SpaceMobile	24.0	-15.5%	13.5%
OMER	Omeros	0.6	-14.2%	-49.1%
VOYG	Voyager Technologies	2.4	-14.0%	57.4%
LUNR	Intuitive Machines	3.2	-13.1%	64.0%
SHAZ	SharonAI	0.9	-12.9%	-32.6%
SWMR	Swarmer	0.7	-12.7%	45.8%
NAVN	Navan	5.0	-11.9%	16.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
VELO	Velo3D	0.5	60.9%	85.6%
TNGX	Tango Therapeutics	4.4	53.0%	249.2%
CBRL	Cracker Barrel Old Country Store	1.0	39.2%	86.6%
ICHR	Ichor	3.0	38.0%	371.0%
NUVL	Nuvalent	9.7	35.5%	22.5%
CNTN	Canton Strategic	0.6	34.3%	2.0%
PAYO	Payoneer Global	2.3	33.9%	20.1%
ELVN	Enliven Therapeutics	2.9	32.9%	199.5%
GLXY	Galaxy Digital	6.4	32.7%	49.2%
UCTT	Ultra Clean	4.9	32.7%	329.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
PCT	PureCycle Technologies	1.6	-29.0%	3.4%
SMCI	Super Micro Computer	18.3	-26.8%	4.1%
SWMR	Swarmer	0.7	-25.6%	45.8%
WOLF	Wolfspeed	1.7	-21.6%	147.8%
NRGV	Energy Vault	0.7	-21.4%	-6.7%
MRLN	Merlin	0.5	-20.8%	-71.0%
SAIL	SailPoint	8.2	-19.8%	-27.7%
PRIM	Primoris Services	5.3	-19.0%	-20.5%
ADBE	Adobe	83.6	-18.9%	-41.7%
TMCR	Metals Royalty	0.5	-18.6%	-33.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
NVRI	Enviri	1.8	295.5%	329.9%
APPS	Digital Turbine	1.1	136.9%	95.2%
HYLN	Hyliion	1.3	106.1%	302.2%
AMC	AMC Entertainment	1.3	75.9%	50.0%
REPL	Replimune	0.8	67.5%	-8.6%
ALAB	Astera Labs	62.7	63.8%	120.7%
UMAC	Unusual Machines	0.9	63.2%	91.8%
GENI	Genius Sports	1.8	62.7%	-37.8%
DELL	Dell Technologies	261.1	62.2%	215.6%
CBRL	Cracker Barrel Old Country Store	1.0	61.3%	86.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
ADCT	ADC Therapeutics	0.2	-69.8%	-70.3%
VRRM	Verra Mobility	0.7	-65.2%	-79.2%
BTGO	BitGo	0.5	-58.2%	-73.1%
FULC	Fulcrum Therapeutics	0.3	-52.4%	-69.5%
LWLG	Lightwave Logic	1.4	-47.4%	196.0%
MRAM	Everspin Technologies	0.6	-41.1%	163.0%
HYMC	Hycroft Mining	2.3	-41.0%	8.4%
OMER	Omeros	0.6	-39.3%	-49.1%
JBIO	Jade Biosciences	0.9	-38.8%	-0.6%
PLAB	Photronics	1.8	-38.7%	-0.7%

Peer Comparisons

Peers to compare with:

Financials

	PGEN	CRSP	NTLA	EDIT	IOVA	NKTX	Median
Name	Precigen	CRISPR T.	Intellia.	Editas M.	Iovance .	Nkarta
Mkt Price	4.45	49.80	12.11	2.50	4.08	2.86	4.27
Mkt Cap	1.6	4.8	1.4	0.2	1.7	0.2	1.5
Rev LTM	32	1	66	39	286	0	35
Op Inc LTM	-90	-646	-421	-89	-358	-116	-237
FCF LTM	-117	-426	-364	-141	-305	-88	-223
FCF 3Y Avg	-87	-301	-388	-169	-353	-104	-235
CFO LTM	-115	-400	-363	-141	-271	-87	-206
CFO 3Y Avg	-83	-289	-382	-165	-330	-94	-227

Growth & Margins

	PGEN	CRSP	NTLA	EDIT	IOVA	NKTX	Median
Name	Precigen	CRISPR T.	Intellia.	Editas M.	Iovance .	Nkarta
Rev Chg LTM	652.1%	-97.1%	45.0%	8.0%	34.3%	-	34.3%
Rev Chg 3Y Avg	184.2%	-5.0%	10.0%	54.7%	-	-	32.4%
Rev Chg Q	1,633.9%	-	-9.5%	-39.2%	44.8%	-	17.7%
QoQ Delta Rev Chg LTM	226.3%	-	-2.3%	-4.5%	8.4%	-	3.0%
Op Inc Chg LTM	3.1%	-36.3%	22.2%	57.0%	10.2%	11.9%	11.1%
Op Inc Chg 3Y Avg	-6.0%	-16.1%	-1.3%	21.1%	4.4%	2.7%	0.7%
Op Mgn LTM	-284.8%	-64,639.5%	-636.6%	-230.1%	-125.4%	-	-284.8%
Op Mgn 3Y Avg	-1,382.7%	-22,035.2%	-935.8%	-358.4%	-8,287.5%	-	-1,382.7%
QoQ Delta Op Mgn LTM	815.9%	-	15.1%	15.1%	25.8%	-	20.4%
CFO/Rev LTM	-365.0%	-39,996.4%	-549.5%	-363.1%	-94.8%	-	-365.0%
CFO/Rev 3Y Avg	-1,064.2%	-13,643.7%	-715.9%	-385.0%	-6,811.7%	-	-1,064.2%
FCF/Rev LTM	-370.2%	-42,617.6%	-550.2%	-364.6%	-106.8%	-	-370.2%
FCF/Rev 3Y Avg	-1,139.6%	-14,519.9%	-727.1%	-394.3%	-7,181.8%	-	-1,139.6%

Valuation

	PGEN	CRSP	NTLA	EDIT	IOVA	NKTX	Median
Name	Precigen	CRISPR T.	Intellia.	Editas M.	Iovance .	Nkarta
Mkt Cap	1.6	4.8	1.4	0.2	1.7	0.2	1.5
P/S	49.9	4,783.4	21.7	6.3	6.0	-	21.7
P/Op Inc	-17.5	-7.4	-3.4	-2.7	-4.8	-1.8	-4.1
P/EBIT	-8.0	-7.4	-3.4	-2.4	-4.8	-1.8	-4.1
P/E	-7.7	-8.4	-3.6	-2.2	-4.8	-2.1	-4.2
P/CFO	-13.7	-12.0	-4.0	-1.7	-6.3	-2.4	-5.1
Total Yield	-13.0%	-11.9%	-27.5%	-44.5%	-20.7%	-47.1%	-24.1%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-14.9%	-7.6%	-30.5%	-102.2%	-21.1%	-51.8%	-25.8%
D/E	0.1	0.2	0.1	0.1	0.0	0.4	0.1
Net D/E	0.0	-0.3	-0.2	-0.4	-0.2	-0.7	-0.3

Returns

	PGEN	CRSP	NTLA	EDIT	IOVA	NKTX	Median
Name	Precigen	CRISPR T.	Intellia.	Editas M.	Iovance .	Nkarta
1M Rtn	0.7%	2.9%	-11.4%	-4.6%	18.3%	8.3%	1.8%
3M Rtn	26.8%	2.2%	-5.1%	2.5%	3.0%	26.5%	2.7%
6M Rtn	20.6%	-12.1%	34.3%	-1.2%	85.5%	52.1%	27.4%
12M Rtn	192.8%	20.4%	45.7%	26.9%	82.1%	53.8%	49.7%
3Y Rtn	250.4%	-15.5%	-73.4%	-73.1%	-52.8%	-42.2%	-47.5%
1M Excs Rtn	7.4%	-5.4%	-15.0%	-13.6%	11.6%	-6.4%	-5.9%
3M Excs Rtn	14.7%	-9.9%	-17.1%	-9.6%	-9.0%	14.5%	-9.3%
6M Excs Rtn	18.9%	-21.4%	21.3%	-11.8%	72.6%	44.2%	20.1%
12M Excs Rtn	173.3%	-3.5%	21.3%	-0.2%	58.7%	19.6%	20.4%
3Y Excs Rtn	163.0%	-94.8%	-146.3%	-150.4%	-124.6%	-115.3%	-120.0%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	3/31/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	5/13/2026	3/25/2026	3/19/2025	3/19/2024	3/6/2023	3/1/2022	3/1/2021
Key Financials
Total Revenue	32	10	4	6	27	14	103
Gross Profit	25	5	-0	0	21	9	48
EBITDA	-194	-244	-123	-89	-62	-78	-68
Operating Income	-90	-107	-95	-89	-75	-91	-86
Net Income	-204	-251	-126	-96	28	-92	-171
EPS	-1.18	-1.37	-0.47	-0.39	0.14	-0.47	-1.02
Growth Rates
Total Revenue Growth	652.1%	146.7%	-36.9%	-76.9%	88.6%	-86.2%	222.5%
EBITDA Growth	-25.3%	-97.2%	-38.4%	-42.9%	20.4%	-15.5%	1.3%
Operating Income Growth	3.1%	-12.6%	-6.5%	-19.2%	18.4%	-6.7%	-0.2%
Net Income Growth	-30.5%	-98.6%	-31.6%	-438.7%	130.7%	46.0%	0.0%
Margins
Gross Margin	80.1%	50.2%	-8.7%	1.7%	76.4%	59.7%	46.2%
EBITDA Margin	-613.9%	-2515.2%	-3146.4%	-1433.3%	-232.0%	-549.9%	-65.8%
Operating Income Margin	-284.8%	-1100.8%	-2412.9%	-1428.5%	-277.3%	-640.7%	-83.0%
Net Income Margin	-647.0%	-2588.2%	-3216.2%	-1540.6%	105.2%	-646.0%	-165.3%
Cash & Debt
Total Cash	56	98	98	63	56	109	100
Total Debt	98	98	6	7	51	190	182
Net Debt / (Cash)	42	0	-92	-56	-5	81	82
Cash Flows & CapEx
Net Cash from Operations	-115	-88	-68	-67	-65	-56	-77
Total CapEx	-2	-2	-9	-2	-5	-7	-8
Free Cash from Operations	-117	-90	-77	-68	-70	-63	-85
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	2	2	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	5/13/2026	3/25/2026	11/13/2025	8/12/2025	5/14/2025	3/19/2025	11/14/2024	8/14/2024	5/14/2024	3/19/2024	11/9/2023	8/9/2023
Key Financials Quarterly
Total Revenue	23	5	3	1	1	1	1	1	1	1	1	2
Ebitda	-4	-19	-145	-26	-54	-19	-23	-59	-22	-32	-18	-19
Operating Income	-6	-22	-34	-28	-23	-23	-21	-26	-24	-23	-21	-21
Net Income	-8	-24	-146	-27	-54	-20	-24	-59	-24	-33	-20	-20
EPS	-0.02	-0.01	-1.06	-0.09	-0.18	-0.06	-0.09	-0.23	-0.10	-0.13	-0.08	-0.08
Key Financials TTM
Total Revenue TTM	32	10	6	4	4	4	4	4	5	6	7	22
Ebitda TTM	-194	-244	-243	-122	-155	-123	-136	-131	-91	-89	-77	-62
Operating Income TTM	-90	-107	-108	-94	-93	-95	-95	-95	-90	-89	-87	-74
Net Income TTM	-204	-251	-247	-124	-157	-126	-140	-135	-97	-96	-85	22
Growth Rates Quarterly
Total Revenue Growth	1633.9%	283.6%	206.6%	19.4%	25.9%	-3.1%	-30.9%	-59.4%	-42.5%	-30.3%	-91.8%	-39.3%
EBITDA Growth	92.7%	-1.3%	-521.0%	55.8%	-141.4%	39.7%	-28.3%	-217.3%	-6.8%	-60.4%	-479.5%	11.0%
Operating Income Growth	73.5%	4.7%	-62.2%	-5.9%	7.4%	2.8%	-1.6%	-24.5%	-4.0%	-7.3%	-175.0%	10.2%
Net Income Growth	85.4%	-19.1%	-510.3%	54.7%	-128.1%	40.3%	-21.1%	-189.3%	-4.4%	-49.1%	-122.7%	-15.2%
Margins Quarterly
EBITDA Margin	-16.9%	-425.0%	-4950.0%	-3038.4%	-3991.3%	-1609.5%	-2443.9%	-8212.4%	-2081.7%	-2586.9%	-1316.2%	-1050.1%
Operating Income Margin	-25.8%	-474.6%	-1180.0%	-3254.3%	-1685.0%	-1910.7%	-2231.1%	-3667.5%	-2292.0%	-1904.6%	-1518.3%	-1195.2%
Net Income Margin	-34.1%	-514.9%	-5008.4%	-3112.4%	-4038.3%	-1657.7%	-2516.1%	-8199.7%	-2228.9%	-2691.9%	-1435.5%	-1149.9%
Cash & Debt
Total Cash	56	98	121	60	80	98	29	20	45	63	74	88
Total Debt	98	98	98	5	5	6	6	6	7	7	7	8
Net Debt / (Cash)	42	0	-23	-55	-75	-92	-23	-13	-38	-56	-66	-80
Cash Flows Quarterly
FCF from Operations	-44	-23	-29	-19	-16	-8	-23	-23	-14	-16	-17	-16
Cash Flows TTM
FCF from Operations TTM	-115	-88	-73	-66	-70	-68	-76	-70	-63	-67	-67	-73
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	1	1	-0	0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-1.0%	-3.7%	-5.9%	-5.4%	-4.4%	-4.4%	-4.0%	-4.9%	-4.8%	-4.6%	-4.2%	-4.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-3.7%	-4.5%	-4.6%	-4.5%	-4.5%	-4.6%	-4.5%	-4.5%	-4.4%	-4.4%	-4.3%	-3.7%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Single segment	10	4
Biopharmaceuticals			0	15	1
Exemplar			6	12	13
Total	10	4	6	27	14

Net Income by Segment

$ Mil	2025	2024
Single segment	-251	-126
Total	-251	-126

Price Behavior

Price Behavior

Market Price	$4.45
Market Cap ($ Bil)	1.6
First Trading Date	08/08/2013
Distance from 52W High	-14.6%
	50 Days	200 Days
DMA Price	$4.12	$4.02
DMA Trend	up	up
Distance from DMA	8.1%	10.7%
	3M	1YR
Volatility	94.1%	105.8%
Downside Capture	110.46	-12.61
Upside Capture	148.77	119.13
Correlation (SPY)	25.8%	17.9%

PGEN Betas & Captures as of 5/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	3.17	1.27	1.61	1.44	1.46	1.77
Up Beta	4.93	0.65	3.70	2.98	3.28	2.11
Down Beta	0.22	1.55	-1.97	-0.32	1.96	1.32
Up Capture	237%	123%	187%	157%	168%	1111%
Bmk +ve Days	13	28	36	67	141	432
Stock +ve Days	11	23	30	59	116	348
Down Capture	463%	257%	176%	140%	-4%	111%
Bmk -ve Days	7	13	27	57	109	318
Stock -ve Days	8	15	28	59	123	365

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with PGEN
PGEN	201.7%	105.4%	1.48	-
Sector ETF (XLV)	15.4%	15.0%	0.74	20.7%
Equity (SPY)	24.9%	12.3%	1.52	17.5%
Gold (GLD)	25.5%	27.4%	0.81	-3.6%
Commodities (DBC)	30.1%	19.0%	1.25	-10.5%
Real Estate (VNQ)	13.5%	13.5%	0.69	17.5%
Bitcoin (BTCUSD)	-41.7%	42.2%	-1.16	10.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with PGEN
PGEN	-8.7%	88.2%	0.28	-
Sector ETF (XLV)	6.4%	14.8%	0.25	26.8%
Equity (SPY)	13.5%	17.1%	0.61	34.4%
Gold (GLD)	16.8%	18.2%	0.75	2.0%
Commodities (DBC)	8.4%	19.4%	0.33	1.3%
Real Estate (VNQ)	2.8%	18.8%	0.05	31.6%
Bitcoin (BTCUSD)	13.6%	54.4%	0.44	19.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with PGEN
PGEN	-16.9%	91.5%	0.20	-
Sector ETF (XLV)	9.7%	16.6%	0.47	28.6%
Equity (SPY)	15.3%	17.9%	0.73	32.4%
Gold (GLD)	12.5%	16.1%	0.64	2.9%
Commodities (DBC)	6.7%	18.0%	0.29	10.0%
Real Estate (VNQ)	5.7%	20.7%	0.24	25.4%
Bitcoin (BTCUSD)	60.3%	66.8%	1.00	12.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	5292026
Short Interest: Shares Quantity	40.3 Mil
Short Interest: % Change Since 5152026	1.0%
Average Daily Volume	4.2 Mil
Days-to-Cover Short Interest	9.6 days
Basic Shares Quantity	354.3 Mil
Short % of Basic Shares	11.4%

Returns Analyses

	Title
0	With Precigen Stock Surging, Have You Considered The Downside?

Earnings Returns History

Updated 6/15/2026

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/13/2026	10.8%	2.9%	7.2%
3/25/2026	25.5%	26.8%	33.2%
11/13/2025	25.6%	1.0%	0.3%
5/14/2025	2.3%	3.1%	18.8%
3/19/2025	0.6%	-10.1%	-22.3%
11/14/2024	-7.1%	2.3%	-23.7%
8/14/2024	-4.5%	6.2%	-6.2%
5/14/2024	5.1%	1.5%	24.1%
...
SUMMARY STATS
# Positive	17	16	14
# Negative	6	7	9
Median Positive	10.6%	6.9%	16.8%
Median Negative	-4.4%	-8.7%	-10.4%
Max Positive	25.6%	36.9%	71.1%
Max Negative	-13.5%	-21.3%	-33.3%

	Forward Returns
5/13/2026	10.8%	2.9%	7.2%
3/25/2026	25.5%	26.8%	33.2%
11/13/2025	25.6%	1.0%	0.3%
5/14/2025	2.3%	3.1%	18.8%
3/19/2025	0.6%	-10.1%	-22.3%
11/14/2024	-7.1%	2.3%	-23.7%
8/14/2024	-4.5%	6.2%	-6.2%
5/14/2024	5.1%	1.5%	24.1%
3/19/2024	0.0%	-2.8%	-8.3%
11/9/2023	-13.5%	-8.7%	-7.9%
8/9/2023	6.9%	31.9%	38.8%
5/10/2023	-4.0%	-3.2%	0.0%
3/6/2023	17.4%	-5.2%	-10.4%
11/9/2022	21.1%	24.5%	6.1%
8/8/2022	12.7%	27.8%	12.2%
5/9/2022	12.2%	11.3%	33.9%
3/1/2022	-4.0%	-10.2%	-4.9%
11/4/2021	-4.4%	-21.3%	-33.3%
8/9/2021	7.9%	4.5%	9.8%
5/10/2021	4.6%	7.5%	14.9%
3/1/2021	4.6%	2.2%	-17.9%
11/9/2020	10.6%	20.3%	71.1%
8/14/2020	13.3%	36.9%	18.8%
SUMMARY STATS
# Positive	17	16	14
# Negative	6	7	9
Median Positive	10.6%	6.9%	16.8%
Median Negative	-4.4%	-8.7%	-10.4%
Max Positive	25.6%	36.9%	71.1%
Max Negative	-13.5%	-21.3%	-33.3%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	05/13/2026	10-Q
12/31/2025	03/25/2026	10-K
09/30/2025	11/13/2025	10-Q
06/30/2025	08/12/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	03/19/2025	10-K
09/30/2024	11/14/2024	10-Q
06/30/2024	08/14/2024	10-Q
03/31/2024	05/14/2024	10-Q
12/31/2023	03/19/2024	10-K
09/30/2023	11/09/2023	10-Q
06/30/2023	08/09/2023	10-Q
03/31/2023	05/10/2023	10-Q
12/31/2022	03/06/2023	10-K
09/30/2022	11/09/2022	10-Q
06/30/2022	08/08/2022	10-Q

Recent Forward Guidance

Updated 6/1/2026

Latest: Q1 2026 Earnings Reported 5/13/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Cash Flow Break-even		0				Higher New

Prior: Q4 2025 Earnings Reported 3/25/2026

null

Insider Activity

Updated 5/27/2026

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Kirk, Randal J	by R.J. Kirk DOT	Sell	3312026	3.30	1,108,998	3,659,693	266,220,299	Form
2	Kirk, Randal J	by JPK 2008	Sell	3312026	3.30	50,797	167,630	1,408,094	Form
3	Kirk, Randal J	by JPK 2009	Sell	3312026	3.30	370,847	1,223,795	10,686,093	Form
4	Kirk, Randal J	by JPK 2012	Sell	3312026	3.30	152,063	501,808	4,829,784	Form
5	Kirk, Randal J	by MGK 2008	Sell	3312026	3.30	50,797	167,630	1,404,916	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Kirk, Randal J		by R.J. Kirk DOT	Sell	3312026	3.30	1,108,998	3,659,693	266,220,299	Form
2	Kirk, Randal J		by JPK 2008	Sell	3312026	3.30	50,797	167,630	1,408,094	Form
3	Kirk, Randal J		by JPK 2009	Sell	3312026	3.30	370,847	1,223,795	10,686,093	Form
4	Kirk, Randal J		by JPK 2012	Sell	3312026	3.30	152,063	501,808	4,829,784	Form
5	Kirk, Randal J		by MGK 2008	Sell	3312026	3.30	50,797	167,630	1,404,916	Form
6	Kirk, Randal J		by MGK 2009	Sell	3312026	3.30	426,199	1,406,457	11,084,426	Form
7	Kirk, Randal J		by MGK 2011	Sell	3312026	3.30	168,794	557,020	4,704,295	Form
8	Kirk, Randal J		by ZSK 2008	Sell	3312026	3.30	47,101	155,433	1,712,901	Form
9	Kirk, Randal J		by ZSK 2009	Sell	3312026	3.30	38,976	128,621	997,303	Form
10	Kirk, Randal J		by Kellie L. Banks LTT	Sell	3312026	3.30	23,789	78,504	1,399,147	Form
11	Kirk, Randal J		by Sunset 2020	Sell	3312026	3.30	2,334,420	7,703,586	40,467,045	Form
12	Kirk, Randal J		by R.J. Kirk DOT	Sell	12222025	4.18	555,119	2,320,397	341,128,329	Form
13	Kirk, Randal J		by JPK 2008	Sell	12222025	4.18	12,909	53,960	1,995,917	Form
14	Kirk, Randal J		by JPK 2009	Sell	12222025	4.18	94,341	394,345	15,085,858	Form
15	Kirk, Randal J		by JPK 2012	Sell	12222025	4.18	38,729	161,887	6,753,350	Form
16	Kirk, Randal J		by MGK 2008	Sell	12222025	4.18	12,909	53,960	1,991,891	Form
17	Kirk, Randal J		by MGK 2009	Sell	12222025	4.18	159,321	665,962	15,821,785	Form
18	Kirk, Randal J		by MGK 2011	Sell	12222025	4.18	42,702	178,494	6,664,333	Form
19	Kirk, Randal J		by ZSK 2008	Sell	12222025	4.18	11,917	49,813	2,366,557	Form
20	Kirk, Randal J		by ZSK 2009	Sell	12222025	4.18	9,931	41,512	1,426,170	Form
21	Kirk, Randal J		by Kellie L. Banks LTT	Sell	12222025	4.18	5,958	24,904	1,871,691	Form
22	Kirk, Randal J		by Kapital Joe	Sell	12222025	4.18	956,200	3,996,916	19,219,824	Form
23	Kindler, Jeffrey B		Direct	Sell	12162025	3.63	235,467	855,899	402,031	Form
24	Kirk, Randal J		by Kapital Joe	Sell	11212025	3.83	937,308	3,589,890	21,272,755	Form
25	Kirk, Randal J		by Kapital Joe	Sell	11212025	4.08	942,832	3,846,755	26,485,532	Form
26	Kirk, Randal J		by Kapital Joe	Sell	11212025	4.47	1,086,153	4,855,104	33,231,696	Form
27	Kindler, Jeffrey B		Direct	Sell	10012025	3.38	106,837	361,109	1,169,717	Form
28	Kindler, Jeffrey B		Direct	Sell	10012025	3.60	67,523	243,083	1,630,465	Form
29	Kirk, Randal J		by Sunset 2020	Sell	9302025	3.41	1,809,667	6,170,964	49,776,319	Form
30	Tennant, Phil	Chief Commercial Officer	Direct	Buy	9302025	3.58	6,000	21,480	232,811	Form
31	Shah, Rutul R	Chief Operating Officer	Direct	Buy	9302025	3.40	2,000	6,800	1,380,261	Form
32	Thomasian, Harry JR	Chief Financial Officer	Direct	Buy	9262025	3.42	2,932	10,027	1,602,701	Form
33	Thomasian, Harry JR	Chief Financial Officer	Direct	Buy	9262025	3.62	8,284	29,988	1,685,812	Form
34	Kirk, Randal J		by Kapital Joe	Sell	9192025	3.68	3,596,892	13,236,563	31,355,576	Form
35	Kirk, Randal J		by Kapital Joe	Sell	9192025	3.86	1,403,360	5,416,970	46,773,276	Form
36	Agee, Nancy H		Direct	Buy	9052025	4.60	15,000	69,000	1,002,069	Form
37	Agee, Nancy H		Direct	Buy	8292025	4.65	10,645	49,491	943,048	Form
38	Agee, Nancy H		Direct	Buy	8292025	3.20	15,360	49,152	615,027	Form

PGEN Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

Diversification Alternatives

How Is The Market Pricing PGEN?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What PGEN Makes & Who Pays

TTM figures based on

PGEN Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 6/14/2026

Precigen (PGEN)

Market Price (6/15/2026): $4.47 | Market Cap: $1.6 BilSector: Health Care | Industry: Biotechnology

Precigen (PGEN)

Market Price (6/15/2026): $4.47Market Cap: $1.6 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Precigen (PGEN)

Precigen (PGEN) Major Products and Platforms

UltraCAR-T Platform (for cancer treatment)

AdenoVerse Immunotherapy (e.g., PAPZIMEOS for Recurrent Respiratory Papillomatosis - RRP)

ActoBiotics Platform (genetically modified bacteria for mucosal sites, e.g., Type 1 Diabetes)

Genetically Engineered Swine (for regenerative medicine/xenotransplantation)

Interactive Breakdown

Better Bets vs. Precigen (PGEN)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for PGEN: 184.2% | 49.9x)

Higher Rev Chg LTM (Value for PGEN: 652.1%)

Higher Rev Chg 3Y Avg (Value for PGEN: 184.2%)

Higher Op Mgn LTM (Value for PGEN: -284.8%)

Higher CFO/Rev LTM (Value for PGEN: -365.0%)

Higher FCF/Rev LTM (Value for PGEN: -370.2%)

Higher Total Yield (Value for PGEN: -13.0%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for PGEN: 184.2% | 49.9x)

Higher Rev Chg LTM (Value for PGEN: 652.1%)

Higher Rev Chg 3Y Avg (Value for PGEN: 184.2%)

Higher Op Mgn LTM (Value for PGEN: -284.8%)

Higher CFO/Rev LTM (Value for PGEN: -365.0%)

Higher FCF/Rev LTM (Value for PGEN: -370.2%)

Higher Total Yield (Value for PGEN: -13.0%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for PGEN: 184.2% | 49.9x)

Higher Rev Chg LTM (Value for PGEN: 652.1%)

Higher Rev Chg 3Y Avg (Value for PGEN: 184.2%)

Higher Op Mgn LTM (Value for PGEN: -284.8%)

Higher CFO/Rev LTM (Value for PGEN: -365.0%)

Higher FCF/Rev LTM (Value for PGEN: -370.2%)

Higher Total Yield (Value for PGEN: -13.0%)

Best Bets in Health Care

P/EBIT (Value for PGEN: -8.0x)

P/E (Value for PGEN: -7.7x)

Rev Chg 3Y Avg (Value for PGEN: 184.2%)

Rev Chg LTM (Value for PGEN: 652.1%)

Rev Chg Q (Value for PGEN: 1633.9%)

FCF/Rev 3Y Avg (Value for PGEN: -1139.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Market Price (6/15/2026): $4.47
Market Cap: $1.6 Bil
Sector: Health Care
Industry: Biotechnology